Aravive (NASDAQ: ARAV) stock up 27% - we think this is unlikely to persist

Aravive (NASDAQ: ARAV) stock is up 27% premarket. This looks very hopeful to us in ARAV stock - we think it likely that this will face away. There is always the option that someone is about to ride over the hill and rescue the company but even if that were to happen we think the recovery for equity would be minimal at best. 

As the word from within the industry has it: “The filing also warns that Aravive may lose the right to develop batiraxcept, its only candidate. The biotech picked the asset up from Stanford University in a deal that gives its partner the power to end the license if it is not “diligently developing and commercializing batiraxcept.” Having ended all trials, and lacking the cash for more studies, Aravive warned investors of the risk of Stanford terminating the deal. Aravive has cut its workforce to the bone to buy time to land a deal. Late last week, the board agreed to reduce its head count by around 70%. Aravive ended last year with 23 full-time employees, suggesting that only a handful of staffers will remain after the cuts. Scott Dove, Ph.D., Aravive’s chief operating officer, is among the employees leaving the company.”

They might need $100 million to rerun the tests on another candidate disease. They’ve not really got much in the way of assets other than that agreement and a little bit of cash. We don’t rate it as a likely recovery to be honest about it. 

r

Aravive Biologics stock price from Google Finance

We’ve talked before about Aravive: “Now this isn’t entirely and wholly true, there may be other cancers it works on and so on but the specific target they were testing for, nope, doesn’t work. From Aravive: “Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any difference between the two arms in the overall population (which included patients previously treated with bevacizumab). The Company will continue to evaluate the complete dataset and determine next steps in the development of batiraxcept.” It may be worth testing on renal cancers and so on but as far as ovarian is concerned, well, no. Doesn’t work.”

It doesn’t work on what they tested it upon, they need $100 million to test it on renal cancers. They’re laying off staff and talking of at least Chapter 11 if not liquidation. Nope, we don’t see that as being up 27%. A flurry of interest perhaps but not a substantive move in our minds.